We tested whether a 13 C-urea breath test can predict antimicrobial resistance of Helicobacter pylori (H. pylori).
T riple therapy, combining a proton pump inhibitor with two antibiotics, is the current standard of therapy for eradicating Helicobacter pylori (H. pylori). [1] [2] [3] [4] [5] Amoxicillin and clarithromycin plus a proton pump inhibitor is the first-line therapy recommended by the Maastricht-2 Consensus group, 1 despite there being H. pylori which are resistant to clarithromycin and amoxicillin. This first-line regimen has a 10% to 23% failure rate. [3] [4] [5] [6] [7] [8] Evaluation of the effectiveness of the eradication regimen with a reliable tool is important. Except for patients with gastric ulcers at risk of gastric malignancy, the 13 C-urea breath test is confirmed as a reliable noninvasive test to assess the treatment outcome of triple therapy. [9] [10] [11] [12] A positive result on the 13 C-urea breath test confirms the failure of the anti-H. pylori eradication therapy. However, the posttreatment value of the 13 C-urea breath test can range widely from less than 10 excessive d 13 CO 2 per ml (ECR) to nearly 40 to 50. The clinical significance of such a wide range of values for the posttreatment 13 C-urea breath test remains uncertain for patients with failed triple therapy. Because clarithromycin resistance of H. pylori is one of the major causes of the failure of triple therapy, 4, 6, 8 it is of clinical interest to test whether the posttreatment of the 13 C-urea breath test can be predictive of clarithromycin resistance of H. pylori in a noninvasive manner. If such a posttreatment value of the 13 C-urea breath test is highly predictive of clarithromycin resistance, it may eliminate the need for follow-up endoscopy in order to take H. pylori culture. Moreover, it may improve the selection of the rescue regimen in primary clinics where routine H. pylori culture is not available. As patients with failed triple therapy need an effective rescue regimen, [13] [14] [15] this study tests whether the posttreatment value of the 13 C-urea breath test can allow physicians to choose a rescue regimen without using an invasive biopsy method. As a secondary aim, we evaluated, in a second sample of patients, the value of the pretreatment 13 C-urea breath test results for predicting clarithromycin resistance.
MATERIALS AND METHODS

Patients and Study Design
Seventy dyspeptic patients, with an initial diagnosis of duodenal ulcer or gastritis only, were consecutively enrolled when 1 week of triple therapy (amoxicillin 1 g, clarithromycin 500 mg, omeprazole 20 mg, twice daily) had failed to eradicate H. pylori. The enrolled patients had at least 5 days of compliance in the previous 1 week of triple therapy. Failure of triple therapy was defined as a positive 13 C-urea breath test with a uniform protocol having an ECR value more than 2.5. 9 The protocol of our breath test for each patient was uniformly applied with 50 mg 13 C-labeled urea (INER-Hp 13 C-tester, Institute of Nuclear Energy Research, Taoyuan County, Taiwan) to collect the baseline and 15-minute gas samples for analyzing the excessive d 13 CO 2 per ml value by continuous flow isotope ratio mass spectrometry (Atomatic Breath Carbon Analyzer, Europa Scientific, Crewe, UK) as in our previous study. 12 The same breath test was performed for each patient during the fifth week after the cessation of triple therapy. Before each urea breath test, medications including proton pump inhibitors, bismuth salt, and antimicrobial agents were withheld for at least the 4 preceding weeks. In addition to these 70 patients who had failed triple therapy, 108 patients with naive H. pylori infection were selected from our database for analysis as the pretreatment group. These 108 patients had no past history of anti-H. pylori therapy and were known to have refrained from exposure to antibiotics, bismuth salts, and proton pump inhibitors before endoscopy and the urea breath test. In the course of usual care, a specimen from each of these patients had demonstrated H. pylori and was tested for resistant organisms. The same protocol for the 13 C-urea breath test was used in these patients as had been used in the patients with failed triple therapy. After obtaining informed consent, each of the 70 patients who had failed triple therapy had endoscopy for H. pylori culture as previously published. 15, 16 The successfully collected H. pylori isolates were then checked for the presence of antimicrobial resistance, defined by the MIC level of an E-test. 15 Each patient had a gastric biopsy for histology to reconfirm H. pylori status, regardless of a positive 13 C-urea breath test. When negative results for both histology and culture were obtained during this follow-up endoscopy, patients were excluded from rescue therapy. All included patients received 1 week of rescue quadruple therapy, including amoxicillin 1 g twice daily, metronidazole 500 mg twice daily, omeprazole 20 mg twice daily, with bismuth subcitrate 120 mg thrice daily. The drug compliance and side effects of rescue therapy were recorded at the next week's visit. The degree of drug compliance was categorized as ''good'' (the 7-day quadruple therapy was completely ingested), ''modest'' (ingested at least 5 days), and ''poor'' (ingested less than 5 days) as used before. 15 A little more than 6 weeks after the rescue regimen, the 13 C-urea breath test was repeated to check for H. pylori eradication. For those with a negative result for the 13 C-urea breath test after quadruple therapy, a repeat 13 C-urea breath test was done during the third month to prevent a false negative result. Thus, both negative results on the 13 C-urea breath test during the sixth week and third month were needed to define successful H. pylori eradication by rescue therapy. The proton pump inhibitors and antibiotics were withheld until the follow-up test. Patients known to be allergic to bismuth or metronidazole were not included. Those patients with gastric malignancy were also excluded.
Endoscopy to Take a Gastric Biopsy for H. pylori Culture and Histology
For each patient, two pairs of gastric biopsy samples (each pair included one from the antrum and the other from the lower body) were obtained during endoscopy. Each pair of biopsies was sent for H. pylori culture and histological staining with hematoxylin and eosin. 15 In cases where gastric ulceration was found during follow-up endoscopy, these cases were excluded. These two bits of gastric biopsy were taken for H. pylori culture, as done in our previous study. 15 were used to determine the parametric difference and nonparametric proportions between the 2 study groups. All tests of significance were two-tailed with a P value less than .05. Data from all of the enrolled patients for rescue therapy were analyzed using intention-to-treat analyses. Patients who stopped medication or had poor drug compliance, or were lost to follow-up after rescue therapy, were excluded from the per-protocol analysis.
RESULTS
Efficacy of the 13 
C-Urea Breath Test to Predict Clarithromycin Resistance of H. pylori
There were 53 H. pylori isolates obtained from the 70 patients who had failed triple therapy. Clarithromycin resistance was found in nearly 66% (35/53) of the H. pylori isolates collected after triple therapy. None of these 53 isolates was proven to have amoxicillin resistance. The mean posttreatment ECR of the 13 C-urea breath test performed after triple therapy was higher in patients with residual H. pylori having clarithromycin resistance than in those without (23.8 vs 10.6; Po.0001).
In Table 1 , we list the test characteristics of the 13 C-urea breath test at several cutoffs for predicting clarithromycin resistance after failed triple therapy. Setting the posttreatment ECR at 415 yielded a sensitivity of 88.6% (95% confidence interval [CI], 78.1 to 99.1) and a specificity of 88.9% (95% CI, 71 to 100) for predicting clarithromycin resistance in residual H. pylori. Furthermore, in our sample, this cutoff point resulted in a positive predictive value of 93.9% (95% CI, 83.6 to 100).
There were no differences in the demographic features, endoscopic diagnoses, side effects, and compliance with rescue therapy between patients with a posttreatment ECR of 13 C-urea breath test 15 and 415 ( Table 2 ). The distribution of metronidazole resistance was also not different between the 2 study groups (P4.05; Table 2 ). The prevalence of clarithromycin resistance was higher in the patients with a posttreatment ECR of 13 Table 3 ).
DISCUSSION
In this study, the mean posttreatment value of the 13 C-urea breath test after triple therapy was higher in the patients with residual H. pylori having clarithromycin resistance than in those without. These data indicate that a higher posttreatment value for the 13 C-urea breath test may be useful in diagnosing clarithromycin resistance in residual H. pylori after failed triple therapy, which had included clarithromycin. Setting the ECR value of the 13 C-urea breath test at 415 after triple therapy had a sensitivity of 88.6% and specificity of 88.9% for predicting the presence of clarithromycin resistance in residual H. pylori. This suggests that the posttreatment value of the 13 Curea breath test may not only indicate the presence of residual H. pylori, but may predict the existence of clarithromycin resistance in these residual bacteria. From a clinical standpoint, this use of a noninvasive test may be very valuable, especially for primary care physicians who need to select rescue regimens without use of endoscopy and culture. For example, if patients have a posttreatment ECR of the 13 C-urea breath testo15, suggesting a low prevalence of clarithromycin resistance, triple therapy with clarithromycin might be repeated.
The reason why residual H. pylori with clarithromycin resistance has a higher posttreatment value for the 13 C-urea breath test remains uncertain. The posttreatment value of the 13 C-urea breath test can be correlated with the urease activity of H. pylori, and thus may be correlated with the bacterial loads of the stomach. 9 We speculate that there is a higher residual H. pylori load due to the poor bacteriocidal effect of clarithromycin on isolates with clarithromycin resistance. It is of research interest to determine whether H. pylori isolates with clarithromycin resistance have higher urease activity or any special urease genomic features. In contrast to the posttreatment value after failed triple therapy, the pretreatment value of the 13 C-urea breath test was not significantly different between patients infected with (n =100) and without (n =8) primary clarithromycin-resistant H. pylori isolates. Before treatment, patients may have abundant bacterial colonization dampening the difference in urease activity between clarithromycin-resistant and-sensitive H. pylori infections.
In this study, only 53 out of 70 patients with histological evidence of infection had a positive H. pylori culture, which may be due to the low residual bacterial load after triple ther- apy. Thus, 24.3% (17/70) of patients after failed triple therapy could not be analyzed for antimicrobial resistance, despite the use of invasive endoscopy for culture. This demonstrates the poor sensitivity of culture of H. pylori, especially after therapy. Our study once again illustrates a hazard in clinical practice, and thus further supports the clinical demand for an addition tool to evaluate posttreatment antimicrobial resistance. As quadruple therapy is the common rescue regimen for failed triple therapy, [13] [14] [15] it is clinically indicated to test whether the posttreatment value of the urea breath test is related to the outcome of rescue therapy. As shown in Table 3 , 1-week quadruple therapy, serving as a rescue regimen, had a 93.8% eradication rate by per-protocol analysis for residual H. pylori, when the posttreatment ECR of the urea breath test was not more than 15, indicating a scanty bacteria load in the stomach. In contrast, for those with an ECR more than 15, the perprotocol eradication rate for residual H. pylori was significantly lower, suggesting that a more potent regimen or a longer duration of the same quadruple therapy should be selected for those patients with a higher posttreatment value after failed triple therapy. Accordingly, the posttreatment value of the urea breath test can provide promising clinical guidance in selecting an optimal regimen to eradicate residual H. pylori, especially in primary clinical service without routine availability of H. pylori culture. In summary, the posttreatment value of the 13 C-urea breath test may be predictive of clarithromycin resistance of residual H. pylori after failed triple therapy, although these results need to be validated in other patient populations.
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